Biovitrum Appoints The Bank of New York Mellon as Depositary Bank
STOCKHOLM - July 7, 2009 - Biovitrum AB (publ) (STO: BVT) has
selected The Bank of New York Mellon (NYSE: BK), as the depositary
bank for its Level I American depositary receipt (ADR) program. Each
Biovitrum ADR represents one common share and trades on the
over-the-counter market. The common shares trade on the Stockholm OMX
Nordic Exchange under the symbol "BVT."
"We are very happy with the agreement with The Bank of New York
Mellon as it has a strong and proven track record," said Martin
Nicklasson, CEO of Biovitrum. "We wish to optimize U.S. investor
access to our share, and we believe the Bank has the resources and
expertise necessary to help us achieve that goal."
"We look forward to helping Biovitrum unlock the potential of the
U.S. capital markets," said Michael Cole-Fontayn, chief executive
officer of The Bank of New York Mellon's Depositary Receipt Division.
"As the world's leading depositary, The Bank of New York Mellon will
utilize its resources to develop a long and mutually beneficial
partnership with Biovitrum and its investors."
About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit www.biovitrum.com
About Bank of New York Mellon
The Bank of New York Mellon acts as depositary for more than 2,100
American and global depositary receipt programs, acting in
partnership with leading companies from 67 countries. With an
unrivalled commitment to helping securities issuers succeed in the
world's rapidly evolving financial markets, the Company delivers the
industry's most comprehensive suite of integrated depositary receipt,
corporate trust and stock transfer services. Additional information
is available at www.bnymellon.com/dr.
For more information please contact:
Biovitrum
Martin Nicklasson, CEO
Phone: +46 8 697 2545
Göran Arvidson, CFO
Cell phone: +46 70 633 30 42
Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on July 7, 2009 at 3.00
p.m. CET.